You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 12, December 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (22)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Articles for Residents
 •Macular Degeneration
 •Alert me on articles by topic

Treatment of Retinal Angiomatous Proliferation in Age-Related Macular Degeneration

A Series of 104 Cases of Retinal Angiomatous Proliferation

Ferdinando Bottoni, MD; Amedeo Massacesi, MD; Mario Cigada, MD; Francesco Viola, MD; Ilenia Musicco, MD; Giovanni Staurenghi, MD

Arch Ophthalmol. 2005;123:1644-1650.

Objective  To report the management of retinal angiomatous proliferation (RAP), a recently described intraretinal neovascular lesion occurring in age-related macular degeneration.

Methods  This was a retrospective review of consecutive patients with age-related macular degeneration who underwent treatment of RAP from January 1, 2000, through January 31, 2003. Inclusion criteria were age 55 years or older, signs of age-related macular degeneration, and diagnosis of RAP based on dynamic indocyanine green angiography. Baseline angiograms were reviewed and RAP was classified into the following 3 stages: stage 1, intraretinal neovascularization, early stage; stage 2, subretinal neovascularization, middle stage; and stage 3, choroidal neovascularization, late stage. Treatment and concomitant treatment results were assessed separately for each RAP stage. The clinical data were statistically analyzed ({chi}2 test and analysis of variance) for 2 main outcome measures—complete obliteration of the lesion and final visual acuity.

Results  Eighty-one patients (99 eyes) with 104 RAPs were identified. Forty-two lesions were at stage 1, 42 at stage 2, and 20 at stage 3. The following 5 treatments were performed: direct laser photocoagulation of the vascular lesion, laser photocoagulation of the feeder retinal arteriole, scatter "gridlike" laser photocoagulation, photodynamic therapy, and transpupillary thermotherapy. Complete obliteration of RAP was achieved in about 24 (57.1%) of the stage 1 lesions (direct laser photocoagulation of the vascular lesion, 73% success rate; photodynamic therapy, 45%), 11 (26.2%) of the stage 2 lesions (scatter gridlike laser photocoagulation, 38% success rate; direct laser photocoagulation of the vascular lesion, 17%), and only 3 (15.0%) of stage 3 lesions (P = .001). Predictive factors with a significant effect on final visual acuity were initial visual acuity (P = .003) and early lesion stage (P = .04). Best final visual acuity was 0.41 (mean, direct laser photocoagulation of the vascular lesion in stage 1) and 0.39 (mean, photodynamic therapy in stage 1), with a mean decrease of 2.5 and 3 lines from baseline, respectively.

Conclusions  Treatment of RAP remains difficult. Early detection of the lesion and subsequent direct conventional laser photocoagulation seems to be associated with better anatomical and functional outcome. Once the vascular complex is well established, anatomical closure is rarely achieved. Further study is warranted to assess the long-term efficacy and the need for re-treatment.


Author Affiliations: Department of Ophthalmology, San Giuseppe Hospital, Milan, Italy (Drs Bottoni, Massacesi, and Cigada); and the Institute of Ophthalmology, Spedali Civili, University of Brescia, Brescia, Italy (Drs Viola, Musicco, and Staurenghi).


RELATED ARTICLE

Retinal Anastomosis to Choroidal Neovascularization: A Bum Rap for a Difficult Disease
Neil M. Bressler
Arch Ophthalmol. 2005;123(12):1741-1743.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combined therapy for retinal angiomatous proliferation with intravitreal triamcinolone and argon laser photocoagulation
Mendis et al.
Br. J. Ophthalmol. 2008;92:1154-1156.
FULL TEXT  

The role of dynamic indocyanine green angiography in the diagnosis and treatment of retinal angiomatous proliferation
Bearelly et al.
Br. J. Ophthalmol. 2008;92:191-196.
ABSTRACT | FULL TEXT  

Expression of VLDLR in the Retina and Evolution of Subretinal Neovascularization in the Knockout Mouse Model's Retinal Angiomatous Proliferation
Hu et al.
IOVS 2008;49:407-415.
ABSTRACT | FULL TEXT  

Biochemical Alterations in the Retinas of Very Low-Density Lipoprotein Receptor Knockout Mice: An Animal Model of Retinal Angiomatous Proliferation
Li et al.
Arch Ophthalmol 2007;125:795-803.
ABSTRACT | FULL TEXT  

Retinal Anastomosis to Choroidal Neovascularization: A Bum Rap for a Difficult Disease
Bressler
Arch Ophthalmol 2005;123:1741-1743.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.